Fred Fowler, MD
Gastroenterology · Charlotte, NCNPI 1326066705
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $766,015 of the $931,916 with a category attached, or 82.2%. 48 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 29.7% of the total. 2025 is the largest year on record at $235,160, 2.3 times the $102,503 reported in 2019. Among gastroenterology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,569 payments — averaging $362.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$276K
- Phathom Pharmaceuticals, Inc.$125K
- AbbVie$125K
- Evoke Pharma, Inc.$109K
- E.r. Squibb & Sons, L.L.C.$51K
- Gilead$50K
- plus $196K from 42 others
Across 84 payments — averaging $3606.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$145K
- AbbVie$80K
- Bristol Myers Squibb$73K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
What the payments were for
- Consulting fees$15,4602%
- Speaking & faculty fees$766,01582%
- Travel & lodging$100,21011%
- Food & beverage$49,9625%
- Education$2690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$931,916 in reported general payments places this provider in the 95th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi On-BodyRisankizumab-Rzaa | 37 | $772,754 |
| GattexTeduglutide | 12 | $477,406 |
| RezdiffraResmetirom | 83 | $332,937 |
| XifaxanRifaximin | 99 | $321,669 |
| LinzessLinaclotide | 264 | $238,230 |
| OcalivaObeticholic Acid | 17 | $233,645 |
| Humira(Cf) PenAdalimumab | 29 | $227,005 |
| SucraidSacrosidase | 15 | $207,873 |
| CreonLipase/Protease/Amylase | 51 | $145,812 |
| ViberziEluxadoline | 49 | $96,104 |
| ZenpepLipase/Protease/Amylase | 32 | $90,281 |
| RinvoqUpadacitinib | 11 | $86,061 |
| IbsrelaTenapanor Hcl | 37 | $78,540 |
| VemlidyTenofovir Alafenamide | 50 | $75,638 |
| Ursodiol | 68 | $60,415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Viberzi, Rinvoq | $124,925 | $566,208375 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gattex, Motegrity | $11,165 | $512,98863 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Trulance, Plenvu | $276,341 | $403,761172 claims |
| Madrigal PharmaceuticalsRezdiffra | $46,287 | $332,93783 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $618 | $233,64517 claims |
| QOL Medical, LLCSucraid | $34,464 | $207,87315 claims |
| Aimmune Therapeutics, Inc.Zenpep | $438 | $90,28132 claims |
| Ardelyx, Inc.Ibsrela | $3,346 | $78,54037 claims |
| GileadVemlidy | $50,109 | $75,63850 claims |
| Evoke Pharma, Inc.Gimoti | $109,228 | $37,83418 claims |
| Redhill Biopharma Inc.Movantik | $16,511 | $31,01974 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $125,096 | $27,57440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 610 gastroenterology providers in North Carolina.
Other gastroenterology in Charlotte
- Stephen DealCharlotte$945K
- Nilesh LodhiaCharlotte$735K
- Oscar BrannCharlotte$136K
- Philippe ZamorCharlotte$132K
- Kent HoltzmullerCharlotte$131K
- Baharak MoshireeCharlotte$105K
- Sagar PatelCharlotte$85K
- Olanrewaju JimohCharlotte$67K
- Sean RudnickCharlotte$60K
- Shailendra ChauhanCharlotte$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.